BridgeBio Oncology Therapeutics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pedro J. Beltran
- Full Time Employees
- 88
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 256 E. Grand Avenue South San Francisco CA United States of America 94080
- IPO Date
- Aug 12, 2025
- CIK
- 0001869105
- Website
- bbotx.com
- Similar Companies
- Business
- BridgeBio Oncology Therapeutics Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics targeting RAS and PI3K malignancies, particularly those driven by KRAS mutations in cancers such as non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma; its lead pipeline includes BBO-8520, a direct KRAS G12C inhibitor binding both ON and OFF states currently enrolling patients in the Phase 1 ONKORAS-101 trial in KRAS G12C-mutant NSCLC alone and with pembrolizumab, BBO-10203 (also known as BBOT-710), an oral RAS-PI3Kα interaction breaker inhibiting RAS-driven PI3Kα-AKT signaling enrolling in the BREAKER-101 trial across HER2+ breast cancer, HR+/HER2- breast cancer, KRAS-mutant colorectal cancer, and KRAS-mutant NSCLC, and BBO-11818, a pan-KRAS inhibitor potent against G12D and G12V mutants enrolling in the KONQUER-101 trial for advanced KRAS-mutant solid tumors, alongside a discovery program targeting additional oncogenic drivers in RAS and PI3K pathways. Originally formed in 2024 as a subsidiary of BridgeBio Pharma Inc. and headquartered in South San Francisco, California, BBOT operates primarily in the United States with a focus on precision oncology for patients lacking adequate treatment options. Recent developments include a $200 million oversubscribed private financing in May 2024 led by Cormorant Asset Management with participation from Omega Funds, Deerfield Management, GV, and others to advance its initial programs into the clinic, followed by the completion in August 2025 of a business combination with Helix Acquisition Corp. II including a $261 million PIPE yielding $382 million in gross proceeds, enabling Nasdaq listing under ticker BBOT and accelerated pipeline progression under CEO Eli Wallace and CSO Pedro Beltran.[function results for pipeline]
Company News
BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Consensus Rating of “Moderate Buy” from Analysts
Brokerages Set BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Price Target at $22.88
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
BBOT to Participate in Upcoming Investor Healthcare Conferences
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives $24.80 Average PT from Brokerages
BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor